Experience

A fine
balance

The passion you want at your side, plus the experience you want at the table.

Meet Our Team

Team

Greater perspectives create greater outcomes.

Balance, diversity and passion are at the core of who we are. Meet the hardworking people who defy convention, shatter glass ceilings, and take companies to the top—all with a unique style and a healthy dose of humor.

Companies

A dynamic
portfolio

Across healthcare and technology, we partner with companies that improve lives.

See Our Companies

Companeis

The future looks bright.

Say hello to our extended family. An impressive roster of agile and imaginative companies that are building the future of healthcare and technology, one big idea at a time. Our portfolio of entrepreneurial muscle includes 59 IPOs and 134 M&As. And counting.

Approach

A hand
in every stage

From the first handshake to the final round, we do what it takes to bring your vision to life.

Learn About Our Approach

About

This is Canaan.

Canaan is an early-stage venture capital firm that invests in visionaries with transformative ideas. While we love speedy success, we’re acutely aware that greatness comes in many forms and at different times. That’s why we’re not afraid to break the mold to bring something spectacular to life.

Experience

A fine
balance

>Quantum Circuits Inc.

The passion you want at your side, plus the experience you want at the table.

Meet Our Team

Companies

A dynamic
portfolio

>IDEAYA Biosciences

Across healthcare and technology, we partner with companies that improve lives.

See Our Companies

Approach

A hand
in every stage

>Berkshire Grey

From the first handshake to the final round, we do what it takes to bring your vision to life.

Learn About Our Approach
Highlight

VentureBeat: Berkshire Grey raises $263 million for industrial robots

Berkshire Grey, which combines AI and robotics to automate omnichannel fulfillment for retailers, ecommerce, and logistics enterprises, today...
Highlight

Endpoints News: RA Capital, Canaan help infuse $50M into Alta-incubated biotech battling acquired resistance to TKIs

Tyra is a biotech “purpose built” to address a surge of acquired resistance to tyrosine kinase inhibitors, where patients’ tumors mutate around the...
Highlight

FierceBiotech: Tyra Biosciences takes aim at treatment-resistant tumors with $50M raise

Tyra is aiming for drivers of drug-resistant tumors to come up with new drugs that work against the mutated, or resistant, form of a protein, as...
Highlight

Announcing three team promotions

We're excited to announce the promotions of Byron Ling, Colleen Cuffaro and Hootan Rashidifard.